Exozymes details NCT pilot commercial readiness

Exozymes Inc. filed a Form 8-K to inform investors that it issued a press release dated January 29, 2026.

Rhea-AI Filing Summary

Exozymes Inc. filed a Form 8-K to inform investors that it issued a press release dated January 29, 2026. The release announces the advancing commercial readiness of the company’s initial NCT pilot run, indicating progress toward moving this early-stage initiative closer to potential commercial use.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Exozymes Inc. (EXOZ) report in its latest 8-K filing?

Exozymes Inc. reported that it issued a press release dated January 29, 2026. The release announces the advancing commercial readiness of the company’s initial NCT pilot run, signaling progress in preparing this pilot effort for potential commercial activity.

What is the main subject of Exozymes Inc.’s January 29, 2026 press release?

The main subject is the advancing commercial readiness of Exozymes Inc.’s initial NCT pilot run. The company highlights that this pilot has progressed to a stage where it is being prepared for potential commercial deployment, prompting disclosure in a Form 8-K filing.

Why did Exozymes Inc. file a Form 8-K related to the NCT pilot run?

Exozymes Inc. filed the Form 8-K to formally disclose a press release about its initial NCT pilot run. By referencing the advancing commercial readiness of this pilot, the company ensured this operational milestone was communicated through an official Securities Exchange Act report.

What exhibit is attached to Exozymes Inc.’s 8-K about the NCT pilot run?

The filing includes Exhibit 99.1, which is a press release dated January 29, 2026. This exhibit provides the detailed announcement about the advancing commercial readiness of Exozymes Inc.’s initial NCT pilot run, as referenced in the 8-K narrative.

On which exchange is Exozymes Inc. (EXOZ) common stock listed?

Exozymes Inc.’s common stock is listed on the Nasdaq Capital Market. The Form 8-K confirms that the company’s common shares trade under the symbol EXOZ, providing investors with the relevant market listing information for its equity securities.

Who signed Exozymes Inc.’s 8-K regarding the initial NCT pilot run?

The Form 8-K was signed on behalf of Exozymes Inc. by Fouad Nawaz. He is identified in the filing as the company’s Vice President, Finance, acting as the duly authorized officer for this report under the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 09:30 PM EST Learn about SEC filing dates

false 0002010788 0002010788 2026-01-29 2026-01-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 29, 2026

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada		001-42204		83-4550057
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (626) 415-1488

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		EXOZ		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 — Other Events.

Attached is a press release dated January 29, 20226, announcing the advancing commercial readiness of the initial NCT pilot run.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits		Description of Exhibit
99.1		Press release dated January 29, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	February 4, 2026	EXOZYMES INC.
		By	/s/ Fouad Nawaz
			Fouad Nawaz,
			Vice President, Finance